The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.

por Hospers, G. A., de Vries, E. G., Mulder, N. H.
Publicado 1990

Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

por Timmer-Bosscha, H., Mulder, N. H., de Vries, E. G.
Publicado 1992

Cisplatin in breast cancer.

por Willemse, P., Sleijfer, D. T., Mulder, N. H., de Vries, E. G.
Publicado 1993

NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinom...

por de Jong, S., Mulder, N. H., de Vries, E. G., Robillard, G. T.
Publicado 1991

When is off-label off-road?

por de Vries, E G E, Cherny, N I, Voest, E E
Publicado 2019

When is off-label off-road?

por de Vries, E G E, Cherny, N I, Voest, E E
Publicado 2019

Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

por Hooiveld-Noeken, J.S., Fehrmann, R.S.N., de Vries, E.G.E., Jalving, M.
Publicado 2019

Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells

por Klimp, A H, Regts, J, Scherphof, G L, de Vries, E G E, Daemen, T
Publicado 1999

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

por Mulder, N. H., Willemse, P. H., Schraffordt Koops, H., de Vries, E. G., Sleijfer, D. T.
Publicado 1990

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

por Meijer, C., Mulder, N. H., Hospers, G. A., Uges, D. R., de Vries, E. G.
Publicado 1990

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.

por Mulder, N. H., de Vries, E. G., Sleijfer, D. T., Schraffordt Koops, H., Willemse, P. H.
Publicado 1992

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

por Garassino, M.C., Vyas, M., de Vries, E.G.E., Kanesvaran, R., Giuliani, R., Peters, S.
Publicado 2021

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.

por de Jong, R. S., Slijfer, E. A., Uges, D. R., Mulder, N. H., de Vries, E. G.
Publicado 1997

Phase I study of 21 days continuous infusion with vindesine.

por de Vries, E. G., Smit, E. F., Vendrig, D. E., Holthuis, J. J., Mulder, N. H.
Publicado 1989

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

por Mulder, P. O., de Vries, E. G., Uges, D. R., Scaf, A. H., Sleijfer, D. T., Mulder, N. H.
Publicado 1990

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

por Mulder, N. H., van der Graaf, W. T., Willemse, P. H., Koops, H. S., de Vries, E. G., Sleijfer, D. T.
Publicado 1994

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.

por Sleijfer, S., Willemse, P. H., de Vries, E. G., van der Graaf, W. T., Schraffordt Koops, H., Mulder, N. H.
Publicado 1996

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores

por Cherny, N.I., Dafni, U., Pentheroudakis, G., Piccart, M., Zygoura, P., Gyawali, B., de Vries, E.G.E.
Publicado 2022

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

por Guchelaar, H. J., Hoekstra, H. J., de Vries, E. G., Uges, D. R., Oosterhuis, J. W., Schraffordt Koops, H.
Publicado 1992

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.

por Groen, H. J., Sleijfer, S., Meijer, C., Kampinga, H. H., Konings, A. W., De Vries, E. G., Mulder, N. H.
Publicado 1995